Literature DB >> 24570921

Selection of patients of hepatocellular carcinoma beyond the Milan criteria for liver transplantation.

See Ching Chan1, Sheung Tat Fan1.   

Abstract

The Milan criteria have been proven to be reliable and easily applicable in selection of patients with small unresectable hepatocellular carcinomas for liver transplantation. It has been repeatedly shown that patients who met these criteria had a 5-year survival of over 70% after transplantation. Such a result is remarkably good for an otherwise incurable malignancy. The main disadvantage of this set of criteria is that it is rather restrictive. Following it religiously denies transplantation to many patients who have tumor stage slightly more advanced. There have been many attempts to extend the criteria to include tumors with larger sizes (as in the UCSF criteria) or with a larger number (as in the Kyoto criteria). Alpha-fetoprotein and PIVKA-II, two biological markers in more aggressive tumors, have also been employed in the selection of patients, and biopsies have been used by the University of Toronto to determine tumor aggressiveness before deciding on transplantation. Patients with tumors beyond the Milan criteria yet not of a high grade have been accepted for transplantation and their survival is comparable to that of transplant recipients who were within the Milan criteria. Preoperative dual-tracer ((11)C-acetate and FDG) positron emission tomography has been used to determine tumor grade, and transarterial chemoembolization has been used to downstage tumors, rendering them meeting the Milan criteria. Patients with downstaged tumors have excellent survival after transplantation. Partial response to chemical treatment is a reflection of less aggressive tumor behavior. Careful selection of patients beyond the Milan criteria with the aid of serum tumor marker assay, positron emission tomography or tumor biopsy allows transplanting more patients without compromising survival. The use of liver grafts either from the deceased or from living donors could thus be justified.

Entities:  

Keywords:  Hepatocellular carcinoma; Milan; liver transplantation

Year:  2013        PMID: 24570921      PMCID: PMC3924653          DOI: 10.3978/j.issn.2304-3881.2012.12.04

Source DB:  PubMed          Journal:  Hepatobiliary Surg Nutr        ISSN: 2304-3881            Impact factor:   7.293


  29 in total

1.  Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival.

Authors:  F Y Yao; L Ferrell; N M Bass; J J Watson; P Bacchetti; A Venook; N L Ascher; J P Roberts
Journal:  Hepatology       Date:  2001-06       Impact factor: 17.425

2.  Preoperative assessment of hepatocellular carcinoma tumor grade using needle biopsy: implications for transplant eligibility.

Authors:  Timothy M Pawlik; Ana L Gleisner; Robert A Anders; Lia Assumpcao; Warren Maley; Michael A Choti
Journal:  Ann Surg       Date:  2007-03       Impact factor: 12.969

3.  Tumor size predicts vascular invasion and histologic grade: Implications for selection of surgical treatment for hepatocellular carcinoma.

Authors:  Timothy M Pawlik; Keith A Delman; Jean-Nicolas Vauthey; David M Nagorney; Irene Oi-Lin Ng; Iwao Ikai; Yoshio Yamaoka; Jacques Belghiti; Gregory Y Lauwers; Ronnie T Poon; Eddie K Abdalla
Journal:  Liver Transpl       Date:  2005-09       Impact factor: 5.799

4.  Hepatic transplantation for primary and metastatic cancers of the liver.

Authors:  I Penn
Journal:  Surgery       Date:  1991-10       Impact factor: 3.982

5.  Liver transplantation for hepatocellular carcinoma: the Kyoto experience.

Authors:  Yasutsugu Takada; Shinji Uemoto
Journal:  J Hepatobiliary Pancreat Sci       Date:  2009-08-26       Impact factor: 7.027

6.  Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis.

Authors:  Francis Y Yao; Robert K Kerlan; Ryutaro Hirose; Timothy J Davern; Nathan M Bass; Sandy Feng; Marion Peters; Norah Terrault; Chris E Freise; Nancy L Ascher; John P Roberts
Journal:  Hepatology       Date:  2008-09       Impact factor: 17.425

7.  A decade of right liver adult-to-adult living donor liver transplantation: the recipient mid-term outcomes.

Authors:  See Ching Chan; Sheung Tat Fan; Chung Mau Lo; Chi Leung Liu; William I Wei; Barbara Hsia-Ying Chik; John Wong
Journal:  Ann Surg       Date:  2008-09       Impact factor: 12.969

8.  Intratumoral DNA heterogeneity of small hepatocellular carcinoma.

Authors:  S Okada; H Ishii; H Nose; T Okusaka; A Kyogoku; M Yoshimori; M Sakamoto; S Hirohashi
Journal:  Cancer       Date:  1995-01-15       Impact factor: 6.860

9.  Living donor liver transplantation for hepatocellular carcinoma: a single-center experience in Taiwan.

Authors:  Allan Concejero; Chao-Long Chen; Chih-Chi Wang; Shih-Ho Wang; Chih-Che Lin; Yueh-Wei Liu; Chin-Hsiang Yang; Chee-Chien Yong; Tsan-Shiun Lin; Bruno Jawan; Tung-Liang Huang; Yu-Fan Cheng; Hock-Liew Eng
Journal:  Transplantation       Date:  2008-02-15       Impact factor: 4.939

10.  18F-FDG-uptake of hepatocellular carcinoma on PET predicts microvascular tumor invasion in liver transplant patients.

Authors:  A Kornberg; M Freesmeyer; E Bärthel; K Jandt; K Katenkamp; J Steenbeck; A Sappler; O Habrecht; D Gottschild; U Settmacher
Journal:  Am J Transplant       Date:  2009-02-03       Impact factor: 8.086

View more
  6 in total

1.  Long-term outcomes of living donor liver transplantation after locoregional treatment for hepatocellular carcinoma: an experience from a single institute.

Authors:  Kenta Inomata; Hiroshi Yagi; Taizo Hibi; Masahiro Shinoda; Kentaro Matsubara; Yuta Abe; Minoru Kitago; Hideaki Obara; Osamu Itano; Shigeyuki Kawachi; Minoru Tanabe; Go Wakabayashi; Motohide Shimazu; Yuko Kitagawa
Journal:  Surg Today       Date:  2020-08-07       Impact factor: 2.549

Review 2.  Surgery and Hepatocellular Carcinoma.

Authors:  Nobuhisa Akamatsu; Umberto Cillo; Alessandro Cucchetti; Matteo Donadon; Antonio Daniele Pinna; Guido Torzilli; Norihiro Kokudo
Journal:  Liver Cancer       Date:  2016-11-29       Impact factor: 11.740

Review 3.  Hepatocellular carcinoma: Surgeon's view on latest findings and future perspectives.

Authors:  Jan Erik Slotta; Otto Kollmar; Volker Ellenrieder; B Michael Ghadimi; Kia Homayounfar
Journal:  World J Hepatol       Date:  2015-05-28

Review 4.  Hepatic radioembolization as a bridge to liver surgery.

Authors:  Arthur J A T Braat; Julia E Huijbregts; I Quintus Molenaar; Inne H M Borel Rinkes; Maurice A A J van den Bosch; Marnix G E H Lam
Journal:  Front Oncol       Date:  2014-07-30       Impact factor: 6.244

5.  A novel combined systemic inflammation-based score can predict survival of intermediate-to-advanced hepatocellular carcinoma patients undergoing transarterial chemoembolization.

Authors:  Chang Liu; Lei Li; Wu-Sheng Lu; Hua Du; Lu-Nan Yan; Tian-Fu Wen; Wu-Ran Wei; Li Jiang; Ming-Qing Xu
Journal:  BMC Cancer       Date:  2018-02-21       Impact factor: 4.430

Review 6.  Current and Future Treatment of Hepatocellular Carcinoma: An Updated Comprehensive Review.

Authors:  Saleh Daher; Muhammad Massarwa; Ariel A Benson; Tawfik Khoury
Journal:  J Clin Transl Hepatol       Date:  2017-12-17
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.